Clinical evaluation of grepafloxacin in the treatment of various infectious diseases in the field of internal medicine

Hiroyuki Kobayashi, Hiroaki Takeda, Hidehiro Watanabe, Hiroshi Ohtami, Susumu Sakayori, Akira Saito, Ichiro Nakayama, Kiyoshi Sato, Masumi Tomizawa, Yohmei Hiraga, Mitsuhide Ohmichi, Kazuo Takebe, Seiichi Murakami, Mitsuo Masuda, Kenichi Imamura, Hisashi Nakahata, Miyoko Saito, Takeshi Osonoi, Masashi Tamura, Kazuki KonishiKazuo Obara, Taro Chiba, Yoji Aoyama, Akiko Shiba, Akira Watanabe, Kazunao Niizuma, Shigeo Takizawa, Yushi Nakai, Yoshihiro Honda, Masataka Katsu, Akira Ohishi, Morio Nakamura, Kotaro Kaneko, Michihiro Sakauchi, Noboru Aosaki, Kaoru Shimada, Hajime Goto, Mieko Goto, Yasuyuki Sano, Yasufumi Miyamoto, Yasuo Arai, Norio Kikuchi, Osamu Sakai, Koya Shiba, Masaki Yoshida, Seiji Hori, Jingoro Shimada, Kihachiro Shimizu, Koichiro Nakata, Tatsuo Nakatani, Eiyasu Tsuboi, Koji Narui, Yoshitaka Nakamori, Hiroko Inagawa, Kyoichi Totsuka, Yusuke Shibata, Ken Kikuchi, Hiromi Hasegawa, Takeshi Mori, Hiroshi Isonuma, Mayumi Takahashi, Tsukasa Ebe, Masayoshi Inagaki, Otohiko Kunii, Atsuko Guji, Isao Ohyatsu, Yasuo Ono, Taku Miyashita, Hajime Nishiya, Yasumasa Tokumura, Hajime Sugiyama, Morimichi Yamaguchi, Masumi Aoki, Toshiaki Haga, Hideo Miyashita, Yasuo Ikeda, Masahiro Kisaki, Shigehisa Mori, Hiroshi Uchida, Yoshio Kobayashi, Koichiro Kudo, Tadashi Horiuchi, Shunsuke Shoji, Junzaburo Kabe, Harumi Shishido, Hideaki Nagai, Koji Satoh, Atsuyuki Kurashima, Shuji Miyake, Kenji Kawakami, Koji Hayashi, Fumio Matumoto, Takeo Imai, Iwao Sakurai, Koji Yoshikawa, Takayuki Takahashi, Masayuki Morita, Shigeki Odagiri, Kaneo Suzuki, Hiroshi Takahashi, Kenichi Takahashi, Takao Okubo, Hirotada Ikeda, Tamotsu Kaneko, Masaaki Arakawa, Nobuki Aoki, Osamu Sekine, Yasutoshi Suzuki, Katsuji Uno, Motohiro Yagi, Hajimu Takeda, Saburo Izumi, Atsuhiko Sato, Kingo Senda, Takafumi Suda, Ryoji Tamura, Atsushi Yoshitomi, Takeshi Yagi, Toshihiko Takeuchi, Yasuo Yamada, Atsushi Nakamura, Toshinobu Yamamoto, Kazuhide Yamamoto, Hidekazu Hanaki, Toshiyuki Yamamoto, Toru Matsuura, Masahiro Yamagoshi, Kanzo Suzuki, Kaoru Shimokata, Satoshi Ichiyama, Hidehiko Saito, Shuzo Sakai, Shiro Nomura, Kazuyoshi Senda, Takeshi Iwahara, Hironobu Minami, Masashi Yamamoto, Hiroshi Saito, Sadaaki Yamori, Tomohisa Shibagaki, Keisuke Nishiwaki, Kazuo Nakanishi, Nobuhiro Narita, Keiichi Mikasa, Masayoshi Sawaki, Mitsuru Konishi, Koichi Maeda, Kaoru Hamada, Shoji Takeuchi, Masahiro Sakamoto, Masayuki Tsujimoto, Mikikazu Kunimatsu, Fumiyuki Kuze, Mitsuru Kawai, Fumio Miki, Yoshiyasu Ikuno, Akihito Murata, Kazuo Sakamoto, Masato Hiruma, Shinichiro Otani, Yasushi Hara, Koji Nakayama, Satohiko Tanaka, Akihisa Hanatani, Saburo Yano, Masaru Nakagawa, Rinzo Soejima, Niro Okimoto, Osamu Moriya, Yoshihito Niki, Toshiharu Matsushima, Makoto Kimura, Yoshihiro Kobashi, Norifumi Adachi, Jun Tanabe, Yoshihiko Tano, Hiroki Hara, Michio Yamakido, Kenji Hasegawa, Tsuyoshi Ogura, Kanji Asada, Osamu Namikawa, Shinsuke Nishioka, Masahiko Azuma, Mikie Maeda, Minoru Shirakami, Yoshiyuki Niho, Yoshiro Sawae, Kaoru Okada, Koji Takaki, Nobuyuki Shimono, Hiroyasu Misumi, Katsuhiko Eguchi, Kotaro Oizumi, Naoto Tokunaga, Yoichiro Ichikawa, Takafumi Yano, Kohei Hara, Shigeru Kohno, Hironobu Koga, Mitsuo Kaku, Kazunori Tomono, Naomi Ito, Koichi Watanabe, Keizo Matsumoto, Masakazu Takasugi, Mikio Taguchi, Kazunori Oishi, Atsushi Takahashi, Hiroshi Watanabe, Akemi Omori, Kiwao Watanabe, Tsuyoshi Nagatake, Hirofumi Tanaka, Soichiro Yamauchi, Tomoku Ichimiya, Kazufumi Hirai, Hiroshi Kawano, Takayoshi Tashiro, Kiyoshi Shima, Shinobu Takenaka, Atsushi Saito, Hiroshi Fukuhara, Yuei Irabu, Jun Inadome, Nobuchika Kusano, Yoshiko Furugen, Isamu Nakasone, Shinko Taira

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Clinical evaluation of grepafloxacin in the treatment of various infectious diseases in the field of internal medicine. The clinical usefulness of grepafloxacin (GPFX), a new quinolone synthesized as an oral antibacterial agent, in various infections in the field of internal medicine was investigated by collaborative research at 62 institutions nationwide. GPFX was administered primarily to patients with respiratory tract infections (RTI), mostly at daily doses of 100~300 mg once or in 2 divided doses. Clinical efficacy was evaluated in 509 of a total of 525 patients for analysis and efficacy was observed in 443 (87.0%) of the 509, including 432 (87.1%) of 496 patients with RTI and 11 (84.6%) of 13 patients with urinary tract infections (UTI). In RTI by disease, clinical efficacy was observed in 19 (86.4%) of 22 patients with pharyngolaryngitis or pharyngitis, 17 (94.4%) of 18 with tonsillitis, 53 (91.4%) of 58 with acute bronchitis, 104 (87.4%) of 119 with pneumonia, 17 (89.5%) of 19 with mycoplasmal pneumonia, 5 (100%) of 5 with atypical pneumonia, 117 (87.3%) of 133 with chronic bronchitis, 48 of 63 with bronchiectasis, 17 (89.5%) of 19 with diffuse panbronchiolitis, and 35 (87.5%) of 40 with secondary infection with chronic respiratory disease. Bacteriological efficacy in RTI was evaluated in 233 patients. Bacteriological eradication was observed in 154 (78.2%) of 197 patients with monomicrobial infection and 22 (61.1%) of 36 with polymicrobial infection. For monomicrobial infection, bacteriological efficacy was higher in patients infected with gram-positive bacteria (48 of 53, 90.6%) than in patients infected with gram-negative bacteria (105 of 142, 73.9%). The MIC80 of GPFX was 0.39 μg/ml in 115 strains of causative organisms in which the MIC80 was determined in RTI, and the MIC80 of norfloxacin (NFLX), ofloxacin (0FLX), enoxacin (ENX) and ciprofloxacin (CPFX) were 6.25, 1.56, 6.25 and 0.78 μg/ml, respectively, in 97 strains. Adverse drug reactions were observed in 26 (5.0%, 38 cases) of 519 patients, including mostly gastrointestinal symptoms, CNS symptoms and hypersensitive symptoms. Abnormal clinical laboratory test values were observed in 49 (10.0%) of 490 patients. Major changes included increased eosinophil and transaminase. None of the reported symptoms or abnormal changes were serious. Based on clinical efficacy, adverse drug reactions and abnormal clinical laboratory test values, GPFX was judged to be useful in 432 (84.7%) of a total of 510 patients, 422 (84.9%) of 497 with RTI and 10 (76.9%) of 13 with UTI. From these results, GPFX was considered to be useful in the treatment of various infectious diseases, particularly RTI, in the field of internal medicine.

Original languageEnglish
Pages (from-to)333-351
Number of pages19
JournalJapanese Journal of Chemotherapy
Volume43
DOIs
Publication statusPublished - 1995

Keywords

  • GPFX
  • grepafloxacin

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Clinical evaluation of grepafloxacin in the treatment of various infectious diseases in the field of internal medicine'. Together they form a unique fingerprint.

  • Cite this

    Kobayashi, H., Takeda, H., Watanabe, H., Ohtami, H., Sakayori, S., Saito, A., Nakayama, I., Sato, K., Tomizawa, M., Hiraga, Y., Ohmichi, M., Takebe, K., Murakami, S., Masuda, M., Imamura, K., Nakahata, H., Saito, M., Osonoi, T., Tamura, M., ... Taira, S. (1995). Clinical evaluation of grepafloxacin in the treatment of various infectious diseases in the field of internal medicine. Japanese Journal of Chemotherapy, 43, 333-351. https://doi.org/10.11250/chemotherapy1995.43.Supplement1_333